NCT02052999

Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients

An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea

Conditions

• Erythematotelangiectatic Rosacea
• Papulopustular Rosacea

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 1%	Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
OTHER	Vehicle	Participants received topical Vehicle twice daily for 8 weeks
DRUG	Rozex gel 0.75%	Participants received topical Rozex gel 0.75% twice daily for 8 weeks

Timeline

• Start date: 2013-02-01
• Primary completion: 2013-06-01
• Completion: 2013-08-01
• First posted: 2014-02-03
• Last updated: 2014-02-03

Locations

1 site across 1 country: South Korea